Use of BGP15 to treat familial dysautonomia

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 10702514
APP PUB NO 20180000809A1
SERIAL NO

15637257

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Disclosed is the use of O-(3-piperidino-2-hydroxy-1-propyl)-nicotinic amidoxime (BGP15), its tautomers, enantiomers and pharmaceutically acceptable salts thereof for the treatment of Familial Dysaustonomia.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
MONTANA STATE UNIVERSITYP O BOX 172460 304 MONTANA HALL BOZEMAN MT 59717-2460
N-GENE RESEARCH LABORATORIES INC575 MADISON AVE 10TH FLOOR NEW YORK NY 10022

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Brownstein, Michael Jay Rockville, US 1 0
Lefcort, Frances Brenda Bozeman, US 1 0

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Jan 7, 2028
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jan 7, 2032
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00